vasopermeation enhancement

vasopermeation enhancement

Oncology An investigational therapy that ↑ up to 3-fold CA cell uptake of chemotherapeutics
References in periodicals archive ?
Peregrine's vascular research programs fall under several different proprietary platforms including Anti-Phospholipid Therapy (APT), Vascular Targeting Agents (VTAs), Anti-Angiogenesis and Vasopermeation Enhancement Agents (VEAs).
Peregrine's vascular research programs fall under several different proprietary platforms including Anti-Phospholipid Therapy, Vascular Targeting Agents, Anti-Angiogenesis and Vasopermeation Enhancement Agents.
Peregrine's Tumor Necrosis Therapy (TNT), Vasopermeation Enhancement Agents (VEA), and Vascular Targeting Agents (VTA) technologies target cell structures and cell types that are common among solid tumor cancers, giving them broad applicability across various tumor types.
Peregrine Pharmaceuticals (Tustin, CA) announced the issuance of United States Patent 6,696,276 that covers its Vasopermeation Enhancement Agent (VEA) technology.
Peregrine has three collateral targeting technologies: Tumor Necrosis Therapy (TNT), Vasopermeation Enhancement Agents (VEA) and Vascular Targeting Agents (VTA).
Peregrine's Tumor Necrosis Therapy (TNT), Vasopermeation Enhancement Agents (VEA), and Vascular Targeting Agents (VTA) target cell structures and cell types that are common among solid tumor cancers, giving them broad applicability across various tumor types.
Peregrine's Tumor Necrosis Therapy, Vasopermeation Enhancement Agents, Vascular Targeting Agents, anti-Angiogenesis Agents, and anti-Phospholipid technologies target cell structures and cell types that are common among solid tumor cancers, giving them broad applicability across various tumor types.
6007817 for Techniclone's Vasopermeation Enhancement Agent ("VEA") technology.
Peregrine's Tumor Necrosis Therapy, Vasopermeation Enhancement Agents, and Vascular Targeting Agents technologies target cell structures and cell types that are common among solid tumor cancers, giving them broad applicability across various tumor types.
The company is also developing two additional technologies for the treatment of solid tumors, Vasopermeation Enhancement Agents (VEA) and Vascular Targeting Agents (VTA).
6,403,096 covering the use of Permeability Enhancing Peptide (PEP) as a Vasopermeation Enhancement Agent (VEA).
Epstein, a professor of pathology at the Keck School of Medicine of the University of Southern California (USC), presented new research demonstrating Peregrine's Vasopermeation Enhancement Agent (VEA) technology can improve the efficacy of some chemotherapeutic drugs for the treatment of various solid tumor cancers.